PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le lundi 03.02.2020 à 10:00 AM CET
Recherche dans les collections de brevets nationales et internationales
Une partie du contenu de cette demande n'est pas disponible pour le moment.
Si cette situation persiste, contactez-nous auObservations et contact
1. (WO2015179657) TRAITEMENT DU CANCER ET INHIBITION DE MÉTASTASES À L'AIDE DE SOUS-UNITÉ BÊTA DE L’HÉMOGLOBINE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WHAT IS CLAIMED IS:

1. A method of screening a subject for micrometastases comprising (a) obtaining a

biological sample from a subject, (b) determining the amount of an HBB peptide in the sample, and (c) comparing to amount determined in (b) with a reference amount.

2. The method of claim 1, wherein when the amount determined in (b) is more than the reference amount, the subject is diagnosed as having micrometastases.

3. The method of claim 1 or 2, wherein the biological sample is serum, blood or sputum.

4. The method of claim 1 or 2, wherein the HBB peptide is human hemoglobin beta subunit (HBB).

5. The method of claim 1 or 2, wherein the amount of an HBB peptide in the biological sample is determined by western blot, dot blot, slot blot, ELISA, RP-HPLC, LC-MS and LC-MS/MS.

6. A method of treating a subject having cancer comprising administering an effective amount of an HBB peptide to a subject having cancer.

7. The method of claim 6, wherein the cancer is selected from the group consisting of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and a cancer of the nervous system.

8. The method of claim 6 or 7, wherein the cancer is neuroblastoma.

9. The method of claim 6 or 7, wherein the HBB peptide comprises the amino acid

sequence ENFRLLGNVLVCVLA, termed HBB lip (SEQ ID NO:5).

10. A methods of inhibiting development of cancer in a subject at risk of developing cancer comprising administering an effective amount of an HBB peptide to a subject at risk of developing cancer.

11. The method of claim 10, wherein the cancer is selected from the group consisting of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and a cancer of the nervous system.

12. The method of claim 10 or 11, wherein the cancer is neuroblastoma.

13. The method of claim 10 or 11, wherein the HBB peptide comprises the amino acid sequence ENFRLLGNVLVCVLA, termed HBB lip (SEQ ID NO:5).

14. The method of claim 10 or 11, wherein the subject at risk of developing cancer is a subject that was previously treated for cancer.

15. The method of claim 10 or 11, wherein the subject at risk of developing cancer is a subject in which cancer was previously cured.

16. A method of inhibiting metastasis of cancer in a subject having cancer comprising administering an effective amount of an HBB peptide to a subject having cancer.

17. The method of claim 16, wherein the cancer is selected from the group consisting of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and a cancer of the nervous system.

18. The method of claim 16 or 17, wherein the cancer is neuroblastoma.

19. The method of claim 16 or 17, wherein the HBB peptide comprises the amino acid sequence ENFRLLGNVLVCVLA, termed HBB lip (SEQ ID NO:5).

20. A pharmaceutical composition comprising one or more HBB peptides and a

pharmaceutically acceptable carrier.

21. The method of claim 20, wherein the HBB peptide comprises the amino acid

sequence ENFRLLGNVLVCVLA, termed HBB lip (SEQ ID NO:5).

22. Use of an HBB peptide in a method of treating a subject having cancer.

23. The use of claim 22, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.

24. The use of claim 22 or 23, wherein the cancer is neuroblastoma.

25. Use of an HBB peptide in a method of inhibiting development of cancer in a subject at risk of developing cancer.

26. The use of claim 25, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.

27. The use of claim 25 or 26, wherein the cancer is neuroblastoma.

28. The use of claim 25 or 26, wherein the subject at risk of developing cancer is a subject that was previously treated for cancer or neuroblastoma.

29. The use of claim 25 or 26, wherein the subject at risk of developing cancer is a subject in which cancer or neuroblastoma was previously cured.

30. Use of an HBB peptide in a method of inhibiting metastasis of cancer in a subject having cancer.

31. The use of claim 30, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.

32. The use of claim 30 or 31, wherein the cancer is neuroblastoma.

33. Use of an HBB peptide for the manufacture of a medicament for treating cancer in a subject.

34. The use of claim 33, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.

35. The use of claim 33 or 34, wherein the cancer is neuroblastoma.

36. Use of an HBB peptide for the manufacture of a medicament for inhibiting

development of cancer in a subject at risk of developing cancer.

37. The use of claim 36, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.

38. The use of claim 36 or 37, wherein the cancer is neuroblastoma.

39. Use of an HBB peptide for the manufacture of a medicament for inhibiting metastasis of cancer in a subject having cancer.

40. The use of claim 39, wherein the cancer may be one or more of breast, cervical, colon, kidney, lung, skin (e.g., melanoma), ovarian, pancreatic, prostate, rectal, stomach, thyroid, cervical, and uterine cancer, and cancer of the nervous system.

41. The use of claim 39 or 40, wherein the cancer is neuroblastoma.